21,22 The benign phenotype of HDAC6 knockout micesuggests that HDAC6 inhibition is a safe therapeutic strategy.23 Overexpression of HDAC6 and confirmed dependencyprofiles in multiple hematological malignancies have accelerated preclinicaland clinical studies of HDAC6-selective inhibitors as single agents,and in combination with lenalidomide, pomalidomide, paclitaxel, bortezomib,or dexamethasone.18,20,24−26. Here, HDAC6 is linked to hematologic disorder.